Osteoarthritis today: Lost in translation?

Elsevier

Available online 13 January 2023, 101810

Best Practice & Research Clinical RheumatologyAuthor links open overlay panelAbstract

Osteoarthritis (OA) is a highly prevalent joint disease that is associated with pain, loss of function, and high direct and indirect economic costs. The current therapeutic options are inadequate, providing only a moderate symptom relief without the possibility of disease modification. While treatment options and personalized medicines are increasing for many complex diseases, OA drug development has been impeded by the advanced state of disease at the time of diagnosis and intervention, heterogeneity in both symptoms and rates of progression, and a lack of validated biomarkers and relevant outcome measures. This review article summarizes the OA landscape, including therapies in development as potential OA treatments, potential biomarkers undergoing evaluation by the US Food and Drug Administration, and a summary of current OA treatment guidelines, with a particular focus on the knee OA.

Keywords

Osteoarthritis

Biomarkers

Drug development

Best practices

OA treatment

© 2022 The Authors. Published by Elsevier Ltd.

留言 (0)

沒有登入
gif